Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent
Highlights
- • The BIOFLOW V trial compared an ultrathin, bioresorbable polymer sirolimus-eluting stent to a thin, durable polymer everolimus-eluting stent. The ultrathin stent had a significantly lower rate of peri-procedural myocardial infarction.
- • This analysis simulated mortality and cost impact of that difference from a U.S. health system perspective over 12 months.
- • The difference was estimated to translate into cost reductions of $124 per patient in 2018 US$, of which 93% accrued to the initial admission.
- • The lower rate of ppMI translates into a gain of 17 quality-adjusted life-years (QALY) per one million patients
Abstract
Objectives
The study estimated the health economic impact of a latest generation coronary stent with ultrathin struts and bioresorbable polymer coating.